Loading...

We've got a brand new version of Simply Wall St! Try it out

Izotropic

CNSX:IZO
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IZO
CNSX
CA$8M
Market Cap
  1. Home
  2. CA
  3. Healthcare
Company description

Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer. The last earnings update was 44 days ago. More info.


Add to Portfolio Compare Print
  • Izotropic has significant price volatility in the past 3 months.
IZO Share Price and Events
7 Day Returns
5%
CNSX:IZO
-3.8%
CA Medical Equipment
1.2%
CA Market
1 Year Returns
5%
CNSX:IZO
-6.4%
CA Medical Equipment
-0.2%
CA Market
IZO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Izotropic (IZO) 5% -3.1% 21.2% 5% - -
CA Medical Equipment -3.8% 0.1% -5.4% -6.4% -43.4% -84.5%
CA Market 1.2% 4.2% 1.5% -0.2% 8.4% 1.8%
1 Year Return vs Industry and Market
  • IZO outperformed the Medical Equipment industry which returned -6.4% over the past year.
  • IZO outperformed the Market in Canada which returned -0.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

IZO Value

 Is Izotropic undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Izotropic. This is due to cash flow or dividend data being unavailable. The share price is CA$0.315.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Izotropic's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Izotropic's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:IZO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in CAD CA$-0.02
CNSX:IZO Share Price ** CNSX (2019-09-11) in CAD CA$0.32
North America Medical Equipment Industry PE Ratio Median Figure of 67 Publicly-Listed Medical Equipment Companies 41.51x
Canada Market PE Ratio Median Figure of 538 Publicly-Listed Companies 14.15x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Izotropic.

CNSX:IZO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:IZO Share Price ÷ EPS (both in CAD)

= 0.32 ÷ -0.02

-17.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Izotropic is loss making, we can't compare its value to the North America Medical Equipment industry average.
  • Izotropic is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Izotropic's expected growth come at a high price?
Raw Data
CNSX:IZO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -17.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Medical Equipment Industry PEG Ratio Median Figure of 58 Publicly-Listed Medical Equipment Companies 2.17x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.98x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Izotropic, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Izotropic's assets?
Raw Data
CNSX:IZO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in CAD CA$0.01
CNSX:IZO Share Price * CNSX (2019-09-11) in CAD CA$0.32
Canada Medical Equipment Industry PB Ratio Median Figure of 15 Publicly-Listed Medical Equipment Companies 5.47x
Canada Market PB Ratio Median Figure of 2,452 Publicly-Listed Companies 1.44x
CNSX:IZO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:IZO Share Price ÷ Book Value per Share (both in CAD)

= 0.32 ÷ 0.01

23.06x

* Primary Listing of Izotropic.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Izotropic is overvalued based on assets compared to the CA Medical Equipment industry average.
X
Value checks
We assess Izotropic's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Izotropic has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IZO Future Performance

 How is Izotropic expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Izotropic has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.6%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Izotropic expected to grow at an attractive rate?
  • Unable to compare Izotropic's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Izotropic's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Izotropic's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:IZO Future Growth Rates Data Sources
Data Point Source Value (per year)
North America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
North America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.9%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:IZO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:IZO Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-04-30 0 0
2019-01-31 0 0
2018-10-31 -1 0
2018-07-31 -1 -1
2018-04-30 -1 -1
2018-01-31 -1 -1
2017-10-31 0 -1
2017-07-31 0 0
2017-04-30 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Izotropic is high growth as no earnings estimate data is available.
  • Unable to determine if Izotropic is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:IZO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Izotropic Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:IZO Past Financials Data
Date (Data in CAD Millions) EPS *
2019-04-30 -0.02
2019-01-31 -0.02
2018-10-31 -0.02
2018-07-31 -0.05
2018-04-30 -0.05
2018-01-31 -0.03
2017-10-31 -0.03
2017-07-31 -0.01
2017-04-30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Izotropic will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Izotropic's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Izotropic's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Izotropic's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Izotropic's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the North America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the North America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Izotropic has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IZO Past Performance

  How has Izotropic performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Izotropic's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Izotropic does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Izotropic's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Izotropic's 1-year growth to the North America Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Izotropic's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Izotropic Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:IZO Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 -0.40 0.31
2019-01-31 -0.42 0.51
2018-10-31 -0.41 0.52
2018-07-31 -0.74 0.54
2018-04-30 -0.73 0.56
2018-01-31 -0.64 0.28
2017-10-31 -0.58 0.22
2017-07-31 -0.17 0.14
2017-04-30 -0.11 0.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Izotropic has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Izotropic has efficiently used its assets last year compared to the North America Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Izotropic improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Izotropic's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Izotropic has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IZO Health

 How is Izotropic's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Izotropic's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Izotropic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Izotropic has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Izotropic's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Izotropic has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Izotropic Company Filings, last reported 4 months ago.

CNSX:IZO Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 0.32 0.00 0.31
2019-01-31 0.44 0.00 0.35
2018-10-31 0.51 0.00 0.39
2018-07-31 0.48 0.00 0.53
2018-04-30 0.41 0.00 0.47
2018-01-31 0.57 0.00 0.58
2017-10-31 0.61 0.00 0.44
2017-07-31 -0.06 0.19 0.15
2017-04-30 -0.06 0.19 0.15
  • Izotropic has no debt.
  • Izotropic currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Izotropic has less than a year of cash runway based on current free cash flow.
  • Izotropic has less than a year of cash runway if free cash flow continues to grow at historical rates of 44.4% each year.
X
Financial health checks
We assess Izotropic's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Izotropic has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IZO Dividends

 What is Izotropic's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Izotropic dividends.
If you bought CA$2,000 of Izotropic shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Izotropic's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Izotropic's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:IZO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 1.2%
Canada Market Average Dividend Yield Market Cap Weighted Average of 333 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Izotropic has not reported any payouts.
  • Unable to verify if Izotropic's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Izotropic's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Izotropic has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Izotropic's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Izotropic afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Izotropic has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IZO Management

 What is the CEO of Izotropic's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bob Thast
COMPENSATION CA$0
AGE 65
TENURE AS CEO 3.3 years
CEO Bio

Mr. Robert Louis Thast, also known as Bob, has been the President and Chief Executive Officer of Maxore Minerals Corp. since March 15, 2007. He has been the President of Thast Projects Inc. since April 1991. He also serves as an Investor Relations Consultant to Pinnacle Mines Ltd. He served as the Chief Executive Officer and President of New Carolin Gold Corp. since March 31, 2014 until June 1, 2018. He is a Promoter of Cap-link Ventures Ltd. He is an Independent Businessman and started Thast Projects in 1986. He served as the Chief Executive Officer of Capstream Ventures Inc. from June 21, 2011 to April 16, 2015 and also served as its Secretary since June 21, 2011. He was Interim President of New Carolin Gold Corp. since April 2014. He has extensive experience with business start- ups and restructurings having worked with such diverse companies as Solid Gold Publications, Hydrozone Inc., International En-R-Tech, Telcom Solutions and Fountain House Holdings. His principal focus is business development, finance and shareholder communications. He has provided management consulting services to various private and public companies through Thast Projects Inc. He served as Corporate Secretary at Capstream since June 21, 2011. Mr. Thast served as the President of Open EC Technologies Inc. from January 20, 1997 to June 18, 1999. He served as the Chief Executive Officer of Petrodorado Energy Ltd. until February 1, 2008 and Cap-link Ventures Ltd. since May 25, 2005. Mr. Thast served as the Chairman, Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer, Treasurer, Compliance Officer of Nova Mining Corp. (now The Radiant Creations Group, Inc.) until September 12, 2008 and served as its Secretary from December 29, 2005 to September 12, 2008. He served as Principal Executive Officer of Nova Mining Corp. and its President since June 2007 until September 12, 2008. From 1988 to 1991, Mr. Thast provided investor and corporate relations work for Camnet Communications. In 1983, he founded Solid Gold Publications and served as its President and Chairman until 1988. From 1974 to 1982, he was a self employed Management Recruiter for Able Personnel. He served as Chief Executive Officer and President of National Telecom Solutions from May 1991 to April 2001, International Savannah Ventures from January 1997 to June 1999 and Calderra Environmental from May 1991 to December 1994. He served as President of Floran Technologies Inc. from 2001 to 2004. Mr. Thast has been a ­Director of Thast Projects Inc. since April 1991 and Maxore Minerals Corp. since March 15, 2007. He has been a Member of Advisory Board of Urban Communications, Inc. since March 22, 2007. He served as a Director of New Carolin Gold Corp. since March 31, 2014 until December 2018. He serves as a Member of Capital Markets Advisory Board at Urban Networks Inc., which he joined in mid 2006. He served as a Director of Capstream Ventures Inc. from June 21, 2011 to May 12, 2016. Mr. Thast served as a Director of Floran Technologies Inc. from 2001 to 2004; Cap-link Ventures Ltd since May 25, 2005; Nova Mining Corp. from December 29, 2005 to September 12, 2005; National Telecom Solutions from May 1991 to April 2001; International Savannah Ventures Inc. from January 1997 to June 1999; Caldera Environmental Inc. from May 1991 to December 1994; Fountain House Holdings from 1994 to 1996 and Mutapa Copper and Cobalt Inc. from September 25, 1997 to March 14, 2003. Mr. Thast served as a Director or Officer of various reporting issuers. Mr. Thast serves as the Chief Executive Officer President, Secretary and Director at Izotropic Corporation since May 19, 2016.

CEO Compensation
  • Insufficient data for Bob to compare compensation growth.
  • Insufficient data for Bob to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Bob Thast

TITLE
CEO, President
AGE
65
TENURE
3.3 yrs

Jody Bellefleur

TITLE
Chief Financial Officer
COMPENSATION
CA$11K
TENURE
1.2 yrs

Marshall Severyn

TITLE
VP of Marketing & Director
Board of Directors Tenure

Average tenure of the Izotropic board of directors in years:

2.3
Average Tenure
  • The average tenure for the Izotropic board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bob Thast

TITLE
CEO, President
AGE
65
TENURE
3.3 yrs

Marshall Severyn

TITLE
VP of Marketing & Director
TENURE
2.3 yrs

Donald Lee

TITLE
Director
AGE
62
TENURE
2.2 yrs

Ali Sodagar

TITLE
Director
TENURE
2.3 yrs

John Boone

TITLE
Director
TENURE
2.3 yrs

Karen Lindfors

TITLE
Member of Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Izotropic's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Izotropic has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IZO News

Simply Wall St News

Does Izotropic's (CNSX:IZO) Share Price Gain of 30% Match Its Business Performance?

To wit, the Izotropic Corporation (CNSX:IZO) share price is 30% higher than it was a year ago, much better than the market return of around -3.0% (not including dividends) in the same period. … We'll need to follow Izotropic for a while to get a better sense of its share price trend, since it hasn't been listed for particularly long. … It's a testament to the popularity of the business plan that the share price gained 30% in the last year, despite the weak balance sheet.

Simply Wall St -

Can We See Significant Insider Ownership On The Izotropic Corporation (CNSX:IZO) Share Register?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Izotropic is a smaller company with a market capitalization of CA$8.1m, so it may still be flying under the radar of many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

IZO Company Info

Description

Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer. It develops and commercializes next generation 3-D breast CT imaging technology for early diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.

Details
Name: Izotropic Corporation
IZO
Exchange: CNSX
Founded: 2016
CA$7,501,882
23,815,499
Website: http://izocorp.com
Address: Izotropic Corporation
800 – 15355 24th Avenue,
Suite 424,
Surrey,
British Columbia, V4A 2H9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX IZO Common Shares Canadian National Stock Exchange CA CAD 04. Jun 2018
OTCPK IZOZ.F Common Shares Pink Sheets LLC US USD 04. Jun 2018
DB 1R3 Common Shares Deutsche Boerse AG DE EUR 04. Jun 2018
Number of employees
Current staff
Staff numbers
0
Izotropic employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/15 01:29
End of day share price update: 2019/09/11 00:00
Last earnings filing: 2019/08/02
Last earnings reported: 2019/04/30
Last annual earnings reported: 2019/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.